Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus

Michael Untch; Peter A. Fasching; Sara Y. Brucker; Wilfried Budach; Carsten Denkert; Renate Haidinger; Jens Huober; Christian Jackisch; Wolfgang Janni; Cornelia Kolberg-Liedtke; David Krug; Thorsten Kühn; Sibylle Loibl; Diana Lüftner; Volkmar Müller; Andreas Schneeweiss; Marc Thill; Nadia Harbeck; Christoph Thomssen

doi:10.1055/a-1483-2782

Geburtshilfe und Frauenheilkunde, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2021; 81(06): 637-653
DOI: 10.1055/a-1483-2782

GebFra Science

Review/Übersicht

Behandlung von Patientinnen mit frühem Mammakarzinom: Evidenz, Kontroversen, Konsens

Meinungsbild deutscher Expert*Innen zur 17. Internationalen St.-Gallen-Konsensuskonferenz Artikel in mehreren Sprachen: English | deutsch

Authors

Michael Untch^*

¹Klinik für Gynäkologie und Geburtshilfe, interdisziplinäres Brustzentrum, HELIOS Klinikum Berlin Buch, Berlin, Germany
Peter A. Fasching^*

²Frauenklinik des Universitätsklinikums Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Sara Y. Brucker^**^#

³Universitäts-Frauenklinik Tübingen, Tübingen, Germany
Wilfried Budach^**

⁴Klinik für Strahlentherapie und Radioonkologie, Universitätsklinik Düsseldorf, Düsseldorf, Germany
Carsten Denkert^**^#

⁵Pathologisches Institut, Philipps Universität Marburg und Universitätsklinikum Marburg (UKGM), Marburg, Germany
Renate Haidinger^*

⁶Brustkrebs Deutschland e. V., Hohenbrunn, Germany
Jens Huober^*^#

⁷Brustzentrum Kantonsspital St. Gallen, St. Gallen, Switzerland

⁸Brustzentrum, Universitätsfrauenklinik Ulm, Ulm, Germany
Christian Jackisch^*

⁹Klinik für Gynäkologie und Geburtshilfe, Sana-Klinikum Offenbach GmbH, Offenbach, Germany
Wolfgang Janni^*

¹⁰Universitätsfrauenklinik Ulm, Ulm, Germany
Cornelia Kolberg-Liedtke^*

¹¹Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Essen, Essen, Germany

¹²palleos healthcare GmbH, Wiesbaden, Germany

¹³Phaon scientific GmbH, Wiesbaden, Germany
David Krug^*

¹⁴Klinik für Strahlentherapie (Radioonkologie), Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany
Thorsten Kühn^*

¹⁵Klinik für Frauenheilkunde und Geburtshilfe, Klinikum Esslingen, Esslingen, Germany
Sibylle Loibl^**^#

¹⁶German Breast Group (GBG), Neu-Isenburg, Germany

¹⁷Centrum für Hämatologie und Onkologie Bethanien, Frankfurt am Main, Germany
Diana Lüftner^*

¹⁸Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie, Charité Campus Virchow-Klinikum, Berlin, Germany
Volkmar Müller^**

¹⁹Klinik und Poliklinik für Gynäkologie, Universitätsklinik Hamburg-Eppendorf (UKE), Hamburg, Germany
Andreas Schneeweiss^*

²⁰Sektionsleiter Gynäkologische Onkologie, Nationales Centrum für Tumorerkrankungen (NCT) Universitätsklinikum Heidelberg, Heidelberg, Germany

²¹Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany
Marc Thill^*

²²Klinik für Gynäkologie und Gynäkologische Onkologie, Interdisziplinäres Brustzentrum, Agaplesion Markus Krankenhaus, Frankfurt am Main, Germany
Nadia Harbeck^*^#

²³Brustzentrum, Frauenklinik, LMU Klinikum, München, Germany
Christoph Thomssen^*

²⁴Universitätsklinik und Poliklinik für Gynäkologie, Martin-Luther-Universität Halle-Wittenberg, Halle (Saale), Germany

Abstract

Zusammenfassung

Die diesjährige 17. St.-Gallen-(SG-)Konsensus-Konferenz zur Behandlung von Patientinnen mit frühem Mammakarzinom (SG-BCC) stand unter dem Motto „Customizing local and systemic therapies for women with early breast cancer“ und fokussierte auf die Herausforderung, die Behandlung des frühen Mammakarzinoms zielgerichteter auf die individuelle Krankheitssituation adaptieren. Wie schon in den vergangenen Jahren hat auch dieses Jahr eine deutsche Arbeitsgruppe führender Brustkrebsexpert*Innen die Ergebnisse der internationalen SG-BCC 2021 vor dem Hintergrund der deutschen Therapieempfehlungen für den Klinikalltag in Deutschland diskutiert. Der Vergleich der SG-Empfehlungen mit den erst kürzlich aktualisierten Therapieempfehlungen der Kommission Mamma der Arbeitsgemeinschaft Gynäkologische Onkologie e. V. (AGO) sowie der S3-Leitlinie ist hilfreich, da sich das SG-BCC-Panel aus Experten unterschiedlicher Länder zusammensetzt, weshalb länderspezifische Besonderheiten in die SG-Empfehlungen einfließen können. Die deutschen Therapieempfehlungen der AGO sowie der S3-Leitlinie basieren auf der aktuellen Evidenz. Gleichwohl muss jede Therapieentscheidung immer einer Nutzen-Risiko-Abwägung für die individuelle Situation unterzogen und mit der Patientin besprochen werden.

Schlüsselwörter

St.-Gallen-Konsensus 2021 - frühes Mammakarzinom - Operation - Strahlentherapie - (neo)adjuvante Systemtherapie - zielgerichtete Therapie

Volltext

Referenzen

References/Literatur
1 AGO Kommission Mamma. Diagnostik und Therapie früher und fortgeschrittener Mammakarzinome (März 2021). Accessed April 18, 2021 at: https://www.ago-online.de/fileadmin/ago-online/downloads/_leitlinien/kommission_mamma/2021/Alle_aktuellen_Empfehlungen_2021.pdf
2 Interdisziplinäre S3-Leitlinie für die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms [Langversion 4.3 Februar 2020). Accessed April 18, 2021 at: https://www.awmf.org/uploads/tx_szleitlinien/032-045OLl_S3_Mammakarzinom_2020-02.pdf
3 Breast International Group. Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA). Accessed April 18, 2021 at: https://clinicaltrials.gov/ct2/show/NCT02032823
4 Nielsen TO, Leung SCY, Rimm DL. et al. Assessment of Ki67 in Breast Cancer: Updated Recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 2020;
5 Fasching PA, Gass P, Häberle L. et al. Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer. Breast Cancer Res Treat 2019; 175: 617-625
6 Wiesner FG, Magener A, Fasching PA. et al. Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients. Breast 2009; 18: 135-141
7 Dettmar P, Harbeck N, Thomssen C. et al. Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer. Br J Cancer 1997; 75: 1525-1533
8 Harbeck N, Gluz O, Kuemmel S. et al. Neoadjuvant nab-paclitaxel weekly versus dose-dense paclitaxel followed by dose-dense EC in high risk HR+/HER2- early BC by: Results from the neoadjuvant part of ADAPT HR+/HER2- trial. San Antonio Breast Cancer Symposium 2020; Abstract No. GS4-03.
9 Smith I, Robertson J, Kilburn L. et al. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. Lancet Oncol 2020; 21: 1443-1454
10 German Breast Group. A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer (IMpassion030). Accessed April 18, 2021 at: https://www.clinicaltrials.gov/ct2/show/NCT03498716
11 NSABP Foundation Inc., German Breast Group. Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo – GeparDouze (GBG 96). Accessed April 18, 2021 at: https://clinicaltrials.gov/ct2/show/NCT03281954
12 Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab – CTX Therapy With Atezolizumab – CTX Therapy (neoMono). Accessed April 18, 2021 at: http://www.clinicaltrials.gov/ct2/show/NCT04770272?term=neomono&draw=2&%20rank=1
13 European Breast Cancer Reseach Association of Surgical Trialists. AXillary Surgery After NeoAdjuvant Treatment (AXSANA). Accessed April 18, 2021 at: https://clinicaltrials.gov/ct2/show/NCT04373655
14 Kuemmel S, Heil J, Rueland A. et al. A Prospective, Multicenter Registry Study to Evaluate the Clinical Feasibility of Targeted Axillary Dissection (TAD) in Node-Positive Breast Cancer Patients. Ann Surg 2020;
15 Caudle AS, Yang WT, Krishnamurthy S. et al. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. J Clin Oncol 2016; 34: 1072-1078
16 Giuliano AE, Ballman KV, McCall L. et al. Effect of Axillary Dissection vs. No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA 2017; 318: 918-926
17 Donker M, van Tienhoven G, Straver ME. et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 2014; 15: 1303-1310
18 NSABP Foundation Inc.. Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery. Accessed April 18, 2021 at: https://clinicaltrials.gov/ct2/show/study/NCT01872975
19 Brunt AM, Haviland J, Sydenham M. et al. FAST Phase III RCT of Radiotherapy Hypofractionation for Treatment of Early Breast Cancer: 10-Year Results (CRUKE/04/015). International Journal of Radiation Oncology*Biology*Physics 2018; 102: 1603-1604
20 Murray Brunt A, Haviland JS, Wheatley DA. et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. The Lancet 2020; 395: 1613-1626
21 Krug D, Baumann R, Combs SE. et al. Moderate hypofractionation remains the standard of care for whole-breast radiotherapy in breast cancer: Considerations regarding FAST and FAST-Forward. Strahlenther Onkol 2021; 197: 269-280
22 Strnad V, Krug D, Sedlmayer F. et al. DEGRO practical guideline for partial-breast irradiation. Strahlenther Onkol 2020; 196: 749-763
23 Evron E, Ben-David AM, Goldberg H. et al. Prophylactic irradiation to the contralateral breast for BRCA mutation carriers with early-stage breast cancer. Ann Oncol 2019; 30: 412-417
24 Krug D, Baumann R, Budach W. et al. Commercially Available Gene Expression Assays as Predictive Tools for Adjuvant Radiotherapy? A Critical Review. Breast Care (Basel) 2020; 15: 118-126
25 van der Noordaa ME, Yau C, Shad S. et al. Assessing prognosis after neoadjuvant therapy: A comparison between anatomic ypAJCC staging, Residual Cancer Burden Class and Neo-Bioscore. San Antonio Breast Cancer Symposium 2020; Abstract No. GS4-07.
26 Mittendorf EA, Vila J, Tucker SL. et al. The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment. JAMA Oncol 2016; 2: 929-936
27 Jeruss JS, Mittendorf EA, Tucker SL. et al. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol 2008; 26: 246-252
28 von Minckwitz G, Huang C-S, Mano MS. et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med 2019; 380: 617-628
29 German Breast Group. Sacituzumab Govitecan in Primary HER2-negative Breast Cancer (SASCIA). Accessed April 18, 2021 at: https://clinicaltrials.gov/ct2/show/NCT04595565
30 McCormick B, Winter K, Hudis C. et al. RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol 2015; 33: 709-715
31 Chua BH, Link E, Kunkler I. et al. GS2-04. A randomized phase III study of radiation doses and fractionation schedules in non-low risk ductal carcinoma in situ (DCIS) of the breast (BIG 3-07/TROG 07.01). San Antonio Breast Cancer Symposium 2020; Abstract No. GS2-04.
32 Wang S-L, Fang H, Song Y-W. et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol 2019; 20: 352-360
33 Danish Breast Cancer Cooperative Group. Hypofractionated Loco-regional Adjuvant Radiation Therapy of Breast Cancer Combined With a Simultaneous Integrated Boost. Accessed April 18, 2021 at: https://clinicaltrials.gov/ct2/show/NCT02384733
34 Alliance for Clinical Trials in Oncology. Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage II a-III a Breast Cancer. Accessed April 18, 2021 at: https://clinicaltrials.gov/ct2/show/NCT03414970
35 Dana-Farber Cancer Institute. Study of Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC) for Invasive Breast Carcinoma. Accessed April 18, 2021 at: https://clinicaltrials.gov/ct2/show/NCT03422003
36 M.D. Anderson Cancer Center. Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer. Accessed April 18, 2021 at: https://clinicaltrials.gov/ct2/show/NCT02912312
37 Marta GN, Ramiah D, Kaidar-Person O. et al. The Financial Impact on Reimbursement of Moderately Hypofractionated Postoperative Radiation Therapy for Breast Cancer: An International Consortium Report. Clin Oncol (R Coll Radiol) 2020;
38 Krug D, Vonthein R, Schreiber A. et al. Impact of guideline changes on adoption of hypofractionation and breast cancer patient characteristics in the randomized controlled HYPOSIB trial. Strahlenther Onkol 2020;
39 Kunkler I, Williams LJ, Jack W. et al. GS2-03. Prime 2 randomised trial (postoperative radiotherapy in minimum-risk elderly): Wide local excision and adjuvant hormonal therapy +/- whole breast irradiation in women =/> 65 years with early invasive breast cancer: 10 year results. San Antonio Breast Cancer Symposium 2020; Abstract No. GS2-03.
40 Vaidya JS, Wenz F, Bulsara M. et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet 2014; 383: 603-613
41 Vaidya JS, Bulsara M, Baum M. et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ 2020; 370: m2836
42 OʼShaughnessy JA, Johnston S, Harbeck N. et al. Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib combined with adjuvant endocrine therapy for high risk early breast cancer. San Antonio Breast Cancer Symposium 2020; Abstract No. GS1-01.
43 Cardoso F, vanʼt Veer LJ, Bogaerts J. et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med 2016; 375: 717-729
44 Sparano JA, Gray RJ, Della Makower F. et al. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 2015; 373: 2005-2014
45 Kalinsky K, Barlow WE, Meric-Bernstam F. et al. First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1 – 3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder). San Antonio Breast Cancer Symposium 2020; Abstract No. GS3-00.
46 West German Study Group. Adj. Dyn. Marker-adjusted Personalized Therapy Comparing Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC (ADAPTlate). Accessed April 18, 2021 at: https://clinicaltrials.gov/ct2/show/NCT04565054
47 West German Study Group. Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs. Chemotherapy in Intermediate Risk, HR+/HER2- EBC (ADAPTcycle). Accessed April 18, 2021 at: https://clinicaltrials.gov/ct2/show/NCT04055493
48 Gonzalez-Angulo AM, Litton JK, Broglio KR. et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 2009; 27: 5700-5706
49 Kang Y-J, Oh SJ, Choi H. et al. Clinical significance of HER2 status in T1 bN0 breast cancer: a nationwide study from the Korean Breast Cancer Society. Breast Cancer Res Treat 2021; 186: 125-134
50 Cancello G, Maisonneuve P, Rotmensz N. et al. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. Breast Cancer Res Treat 2011; 127: 713-720
51 Villasco A, Actis S, Borella F. et al. Evaluation of the efficacy of Trastuzumab in patients with HER2 positive small (pT1mi/a) breast cancers. A multicenter retrospective study on 100 patients. The Breast 2021; 56: S17-S18
52 Reimer T, Stachs A, Nekljudova V. et al. Restricted Axillary Staging in Clinically and Sonographically Node-Negative Early Invasive Breast Cancer (c/iT1–2) in the Context of Breast Conserving Therapy: First Results Following Commencement of the Intergroup-Sentinel-Mamma (INSEMA) Trial. Geburtshilfe Frauenheilkd 2017; 77: 149-157
53 Cold S, Cold F, Jensen M-B. et al. 1814 Vaginal estrogens and risk of recurrence or death in women treated for estrogen receptor positive breast cancer. Eur J Cancer 2015; 51: S270
54 Smetanay K, Junio P, Feißt M. et al. COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer. Breast Cancer Res Treat 2019; 173: 135-143
55 Rugo HS, Voigt J. Scalp Hypothermia for Preventing Alopecia During Chemotherapy. A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clin Breast Cancer 2018; 18: 19-28
56 Nangia J, Wang T, Osborne C. et al. Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial. JAMA 2017; 317: 596-605